Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...
Biopharma M&A, licensing upfronts and VC all cooled in Q3, DealForma data show, while China’s share of pharma in-licensing kept climbing.
Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board.
Alnylam & Regeneron's siRNA therapy brezosiran reduced mutant huntingtin protein 60-64% in 9 patients, spurring plans for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results